Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019

May 6, 2019

  • Enrollment rate now at 90%
  • Key Opinion Leader endorsement of the potential for NCX 470 in intraocular pressure (IOP) lowering

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 Phase 2 clinical study Dr. Thomas Walters MD delivered a podium presentation at the annual meeting of the American Society of Cataract and Retinal Surgery (ASCRS) 2019 in San Diego updating on the progress of the NCX 470 Phase 2 clinical study in patients with glaucoma or ocular hypertension.

The presentation highlighted that the 420-patient study, which started in August 2018, was progressing well, having reached 90% enrollment. The presentation also highlighted the potential for NCX 470 to become the best-in-class first line therapy for lowering intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog which is currently in a multicenter, U.S. Phase 2 clinical study for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Top-line data is expected in Q4 of this year

ASCRS 2019 took place from May 3-May 7, 2019 in San Diego, United States. The presentation was entitled Site Initiation Rates and Subject Enrollment Rates for 28-Day, First-in-Human Phase 2 Clinical Study of NCX 470: Novel NO-Donating Bimatoprost Analog.

← Back to blog page